Interpreting Key Trials

In heart failure, all beta-blockers are not necessarily equal

Interpreting the COMET trial

Author and Disclosure Information

ABSTRACTThe Carvedilol or Metoprolol European Trial (COMET; Lancet 2003; 362:7-13) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol tartrate. Whether the target doses used were equivalent (carvedilol 25 mg twice daily vs metoprolol tartrate 50 mg twice daily) has been debated, but the COMET trial shows that drugs in the same class do not necessarily have the same effects. Given the overwhelming evidence of the benefit of carvedilol, metoprolol succinate, and bisoprolol in patients with heart failure, we should all strive to increase the use of these drugs in appropriate doses.


Next Article:

Atrial fibrillation

Related Articles

  • From the Editor

    Up pops the devil

    The COMET trial is important for the treatment of heart failure, but the devil is in the details.